UK medicines with clinical-trial evidence for a new indication
31 of the 583 medicines with a UkTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (13 at L1, 18 at L2), meaning clinical-trial evidence (randomised trials, Phase 2–3 trials or systematic reviews) was found for it.
The medicines come from the NHSBSA BNF code information (medicines in current NHS prescribing use; MHRA licence status is not included), and the list below reflects the drug reports as last updated on 2026-11-03.
Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.
Medicines with trial evidence (L1–L2)
| Drug | Predicted new indication | Evidence level | Registered trials cited (NCT) |
|---|---|---|---|
| Bromfenac | Eye disease (broad category) | L1 | 10 |
| Busulfan | Myelodysplastic syndrome | L1 | 10 |
| Clomipramine | Anxiety disorder | L1 (with caveat) | 8 |
| Dapsone | Pneumocystosis | L1 | 10 |
| Ketamine | Headache disorder | L1 (with caveat) | 9 |
| Ketorolac | Headache disorder | L1 (with caveat) | 10 |
| Letrozole | Nipple carcinoma | L1 | 10 |
| Montelukast | Bronchitis | L1 (with caveat) | 10 |
| Nepafenac | Eye disease | L1 | 10 |
| Ribavirin | Chronic hepatitis B virus infection | L1 (with caveat) | 16 |
| Rifabutin | HIV infectious disease (in practice, HIV-associated opportunistic mycobacterial disease) | L1 | 10 |
| Tacrolimus | Seborrheic dermatitis | L1 | 2 |
| Tizanidine | Migraine disorder | L1 (with caveat) | 2 |
| Atorvastatin | HIV infectious disease | L2 | 10 |
| Bupropion | attention deficit-hyperactivity disorder | L2 | 6 |
| Dasatinib | Ewing sarcoma | L2 (with caveat) | 2 |
| Everolimus | liposarcoma | L2 | 1 |
| Lamotrigine | Trigeminal nerve neoplasm | L2 | 2 |
| Lenalidomide | Myeloid leukemia | L2 | 11 |
| Mefenamic Acid | Headache disorder | L2 | 0 |
| Mercaptopurine | Myeloid leukemia | L2 (with caveat) | 10 |
| Moclobemide | Agoraphobia | L2 | 0 |
| Mycophenolate Mofetil | HIV infectious disease | L2 (with caveat) | 4 |
| Nortriptyline | Attention deficit-hyperactivity disorder | L2 | 0 |
| Pimecrolimus | Seborrheic dermatitis | L2 | 2 |
| Prednisolone | Alopecia areata | L2 | 0 |
| Prednisone | Alopecia areata | L2 | 0 |
| Sorafenib | Liposarcoma | L2 | 7 |
| Sucralfate | Duodenogastric reflux | L2 | 0 |
| Sunitinib | Liposarcoma | L2 | 2 |
| Trazodone | Obsessive-compulsive disorder | L2 | 0 |
How to read this list
- Evidence level follows the methodology: L1 = multiple Phase 3 RCTs or systematic reviews; L2 = a single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
- Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, so some predictions may still overlap an established use; the report explains this where it applies.
- Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
- For all levels, see High Evidence (L1-L2) and All Drugs.
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)